Biotechnology company developing targeted radiopharmaceutical therapies for cancer.
RayzeBio, Inc. focuses on advancing radiopharmaceutical therapeutics (RPT) designed to combat cancer. The company's flagship drug candidate, RYZ101, is currently undergoing phase 3 clinical trials aimed at treating gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). In addition to RYZ101, RayzeBio is developing a robust pipeline that includes RYZ801, a proprietary peptide targeting GPC3 for delivering Ac225 to treat hepatocellular carcinoma (HCC). They are also advancing RYZ811, a paired diagnostic imaging agent featuring a peptide binder, chelator, and Ga68 as the radioisotope. Another key development is a proprietary small molecule targeting CA9 to deliver Ac225 for treating clear cell renal cell carcinoma (ccRCC).
Founded in 2020 and headquartered in San Diego, California, RayzeBio, Inc. has quickly emerged as a significant player in the field of radiopharmaceuticals. Their innovative approach leverages targeted therapies to address critical unmet needs in cancer treatment. The company's commitment to advancing therapeutic options is underscored by their pipeline's focus on novel peptides and small molecules designed to improve patient outcomes across various cancer types.
RayzeBio, Inc. achieved a pivotal milestone on February 26, 2024, when it became a subsidiary of Bristol-Myers Squibb Company. This strategic partnership enhances RayzeBio's capabilities to accelerate the development and commercialization of its cutting-edge RPTs. By leveraging Bristol-Myers Squibb's resources and expertise, RayzeBio aims to expand access to its innovative therapies and bring meaningful advancements to cancer patients worldwide.
With a dedicated team and a strong foundation in scientific research, RayzeBio, Inc. continues to pioneer new avenues in oncology treatment. Their collaborations and pipeline advancements position them at the forefront of the radiopharmaceutical industry, driving towards transformative therapies that address the complexities of cancer with precision and efficacy.